“These results indicate that temporarily inhibiting the action of glucocorticoids through pharmacological inhibitors can substantially boost the effectiveness of growth factor-based regenerative therapies. If validated in humans, this strategy could have a significant impact on the treatment of heart failure.”
Complements the RBM22 paper; part of renewed focus on cardiac regeneration at basic science level with potential pharmacologic repurposing.
Celik et al. (2026) studied this question.